The invention provides nicotine receptor agonists of formula I:
1
wherein R
1
, x, y, and n have any of the values given in the specification, or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising such a compound or salt, methods for preparing such a compound or salt, and methods for modulating (e.g. antagonizing or activating) nicotine receptors with such a compound or salt.
2-(2-Piperidyl)- and 2-(2-Pyrrolidyl)chromans as Nicotine Agonists: Synthesis and Preliminary Pharmacological Characterization
作者:Simon M. N. Efange、Zhude Tu、Krystyna von Hohenberg、Lynn Francesconi、Robertha C. Howell、Marilyn V. Rampersad、Louis J. Todaro、Roger L. Papke、Mei-Ping Kung
DOI:10.1021/jm010129z
日期:2001.12.1
As part of an effort to develop a new class of subtype selective nicotine agonists, we have synthesized and tested a group of 12 hydroxylated 2-(2-piperidyl)- and 2-(2-pyrrolidyl)chromans. In rat brain membranes, all 12 compounds displayed poor affinity for [(125)I]-alpha-bunagarotoxin binding sites. In contrast, three compounds, 17c, 24, and 26, displayed moderate to high affinity for [(3)H]cytisine
Inhibitory Kinetics of Azachalcones and their Oximes on Mushroom Tyrosinase: A Facile Solid-state Synthesis
作者:Sini K. Radhakrishnan、Ronald G. Shimmon、Costa Conn、Anthony T. Baker
DOI:10.1002/cbdv.201500168
日期:2016.5
azachalcones and their oximes as tyrosinase inhibitors. Their inhibitory activities on mushroom tyrosinase using l‐3,4‐dihydroxyphenylalanine as a substrate were investigated. Two of the novel oxime derivatives synthesized were seen to be more potent than the positive control, kojicacid. Both the compounds 1b and 2b inhibited the diphenolase activity of tyrosinase in a dose‐dependent manner with their